Product image of Mirena (Levonorgestrel) supplied by GNH India

Mirena

Active Ingredient:
Levonorgestrel
Origin:
EU

Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg intrauterine system (IUS) for intrauterine use. It provides highly effective, reversible birth control, reduces heavy menstrual bleeding, and offers endometrial protection for women receiving estrogen therapy.

GNH India supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across markets. The company adheres to EU GMP standards and provides technical support for product handling.

Manufacturer / TM Owner

Jenapharm Gmbh & Co Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levonorgestrel released from Mirena acts within the reproductive hormonal axis to deliver long‑term contraception and therapeutic control of uterine bleeding.

  • Contraception: Provides highly effective, reversible birth control for women of reproductive age.
  • Heavy menstrual bleeding: Reduces menstrual blood loss and improves anemia associated with excessive bleeding.
  • Endometrial protection: Prevents estrogen‑induced endometrial hyperplasia in women receiving combined hormone therapy.

How It Works

  • Mirena continuously releases a low dose of levonorgestrel directly into the uterine cavity. Levonorgestrel binds to progesterone receptors in the endometrium, leading to endometrial atrophy, thickening of cervical mucus, and suppression of the luteinizing hormone surge, which together inhibit ovulation and create an environment hostile to sperm and implantation.

Side Effects

Levonorgestrel delivered via Mirena may be associated with a range of local and systemic adverse reactions.

Common Side Effects

  • Irregular bleeding or spotting
  • Amenorrhea (absence of periods)
  • Cervical discharge
  • Headache
  • Breast tenderness
  • Acne

Serious or Rare Side Effects

  • Uterine perforation
  • Pelvic inflammatory disease
  • Ectopic pregnancy
  • Ovarian cyst formation
  • Hormone‑dependent tumor growth
  • Allergic reaction (e.g., rash, anaphylaxis)

Precautions & Warnings

  • Prior to insertion and during use, several precautions should be observed to ensure safety and optimal performance of Mirena.
  • Screen for contraindications: Ensure patient has no active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel.
  • Pregnancy status: Confirm patient is not pregnant before insertion.
  • Timing of insertion: Insert within 5 days of menstrual onset or after a negative pregnancy test.
  • Follow‑up: Schedule evaluation 4–6 weeks post‑insertion to assess placement and bleeding pattern.
  • Removal considerations: Remove before expiry (5 years) or if complications arise.
  • Store at room temperature: Keep device in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Levonorgestrel may interact with other medicines that affect its metabolism or hormonal activity.

Major Interactions (Avoid)

  • Enzyme inducers (e.g., rifampin, carbamazepine): May reduce levonorgestrel effectiveness.
  • Antifungal azoles (e.g., ketoconazole): May increase systemic levonorgestrel levels.
  • Antiretroviral drugs (e.g., efavirenz): May lower contraceptive efficacy.

Moderate Interactions (Monitor Closely)

  • Hormonal therapies (e.g., combined oral contraceptives): May alter bleeding patterns.
  • Antibiotics (e.g., tetracycline): Limited evidence of interaction, monitor for breakthrough bleeding.
  • Herbal supplements (e.g., St. John’s wort): Potential enzyme induction, observe efficacy.

Frequently Asked Questions

Mirena is an intrauterine system that releases levonorgestrel to provide highly effective contraception, reduce heavy menstrual bleeding, and protect the endometrium in women who are receiving estrogen‑containing hormone therapy.

Levonorgestrel binds to progesterone receptors in the uterine lining, causing endometrial thinning, thickening cervical mucus, and suppressing the luteinizing hormone surge. These actions together inhibit ovulation and create an environment that prevents sperm penetration and implantation.

Mirena is a pre‑loaded 52 mg intrauterine system that releases a low, steady dose of levonorgestrel over up to five years. The exact dosing regimen is determined by the prescribing clinician and is not adjusted by the patient.

Mirena is classified as pregnancy category X and must not be used in women who are pregnant or who intend to become pregnant. Limited data suggest it is compatible with breastfeeding, but clinicians usually evaluate risks and benefits before continuation after delivery.

To order Mirena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral contraceptives, Mirena offers a once‑in‑five‑year dosing interval, higher contraceptive efficacy, and additional therapeutic benefits such as reduction of heavy menstrual bleeding. Unlike depot injections, it does not require periodic clinic visits for re‑administration.

Mirena should be stored at room temperature, ideally below 25 °C, in its original packaging. Protect the device from moisture and direct sunlight until the time of insertion to maintain the integrity of the hormone‑release system.

Mirena is inserted by a qualified health‑care professional into the uterine cavity through the cervical canal. The procedure is performed in a clinical setting, usually within five days of the start of a menstrual period or after a confirmed negative pregnancy test.

Serious risks include uterine perforation during insertion, pelvic inflammatory disease, ectopic pregnancy if contraception fails, and rare hormone‑dependent tumor growth. Patients should be educated to seek immediate medical attention for severe abdominal pain, abnormal bleeding or signs of infection.

Mirena is contraindicated in women with active pelvic infection, unexplained vaginal bleeding, known hypersensitivity to levonorgestrel, current pregnancy, or a history of uterine perforation. It should also be avoided in patients with certain liver diseases or hormone‑sensitive cancers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.